1. Home
  2. BLUE vs BOLD Comparison

BLUE vs BOLD Comparison

Compare BLUE & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLUE
  • BOLD
  • Stock Information
  • Founded
  • BLUE 1992
  • BOLD 2018
  • Country
  • BLUE United States
  • BOLD United States
  • Employees
  • BLUE N/A
  • BOLD N/A
  • Industry
  • BLUE Biotechnology: Biological Products (No Diagnostic Substances)
  • BOLD
  • Sector
  • BLUE Health Care
  • BOLD
  • Exchange
  • BLUE Nasdaq
  • BOLD Nasdaq
  • Market Cap
  • BLUE 36.9M
  • BOLD 30.3M
  • IPO Year
  • BLUE 2013
  • BOLD 2024
  • Fundamental
  • Price
  • BLUE $4.98
  • BOLD $1.49
  • Analyst Decision
  • BLUE Hold
  • BOLD Hold
  • Analyst Count
  • BLUE 7
  • BOLD 1
  • Target Price
  • BLUE $44.60
  • BOLD N/A
  • AVG Volume (30 Days)
  • BLUE 750.4K
  • BOLD 57.3K
  • Earning Date
  • BLUE 05-20-2025
  • BOLD 05-09-2025
  • Dividend Yield
  • BLUE N/A
  • BOLD N/A
  • EPS Growth
  • BLUE N/A
  • BOLD N/A
  • EPS
  • BLUE N/A
  • BOLD N/A
  • Revenue
  • BLUE $83,807,000.00
  • BOLD N/A
  • Revenue This Year
  • BLUE $218.58
  • BOLD N/A
  • Revenue Next Year
  • BLUE N/A
  • BOLD N/A
  • P/E Ratio
  • BLUE N/A
  • BOLD N/A
  • Revenue Growth
  • BLUE 184.12
  • BOLD N/A
  • 52 Week Low
  • BLUE $3.56
  • BOLD $1.06
  • 52 Week High
  • BLUE $28.60
  • BOLD $12.26
  • Technical
  • Relative Strength Index (RSI)
  • BLUE 63.73
  • BOLD N/A
  • Support Level
  • BLUE $3.20
  • BOLD N/A
  • Resistance Level
  • BLUE $4.45
  • BOLD N/A
  • Average True Range (ATR)
  • BLUE 0.20
  • BOLD 0.00
  • MACD
  • BLUE 0.04
  • BOLD 0.00
  • Stochastic Oscillator
  • BLUE 99.44
  • BOLD 0.00

About BLUE bluebird bio Inc.

bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.

About BOLD Boundless Bio Inc. Common Stock

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Share on Social Networks: